

Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials

Aurélien Rondon, Jacques Rouanet and Françoise Degoul

Table S1. Details of anti-CD20 RIT for non-solid cancers in clinical trials, from 2010 to 2021.

Target/ Vector	Isotope	Cancer type ¹	Phase ²	n ³	Line of treatment ⁴	Associa- tion ⁵ (+/−)	SCT (Auto/ Allo/−)	Cold mAb (+/−)	Fraction- ation* (+/−)	PFS median (months) or X-years PF ⁶ (%)	OS median (months) or X-years OS (%)	ORR (%)	CR (%)	NCT (or eq.), [Ref]
<i>Ibritumomab tiuxetan</i>	Y-90	FL	II	74	1 st line	−	−	+	+	40.2 3y: 58 %	NR 3y: 95 %	94	58	NCT01493479, [40]
		FL	II	50	1 st line	−	−	+	−	NR	NR	94	86	− [41]
		FL	II	59	1 st line	−	−	+	−	25.9	NR	87	56	NCT00772655, [12]
		FL	I/II	47	Conditioning (R/R)	+(C)	−	+	−	NR 3y: 85%	NR 3y: 88%	−	−	NCT00048737, [26]
		FL	II	61	Consolidation	+(C)	−	+	−	NR 6y: 68%	NR 6y: 93%	−	38	− [10]
		FL	II	55	Consolidation	+(C)	−	+	−	NR	NR	96	69	NCT00859001, [11]
		FL	II	52	Consolidation (R/R)	+(C)	−	+	−	23.1	NR	98	30	NCT00637832, [46]
		FL	III	207	Consolidation	+(C)	−	+	−	49.2	NR	81	59	NCT00185393, [45]
		FL	II	24	Consolidation (R/R)	+(C)	−	+	−	NR 2 y: 59 %	NR 2y: 95%	88	83	− [47]
		FL	I	9	R/R	+(C)	−	+	−	−	−	89	33	− [48]
		FL MZL	II	31	1 st line	−	−	+	−	NR	NR	100	97	NCT00493467, [42]
		MZL	II	16	1 st line	−	−	+	−	47.6 5 y: 40%	NR 5 y: 72%	88	56	NCT00453102, [43]
		FL MZL	II	20	Consolidation	+(C)	−	+	−	47.2	NR	100	79	− [13]
		MZL	P	30	R/R	−	−	+	−	NR	NR	90	77	− [50]
		MCL	Retro	46	Conditioning	+(C)	Auto	+	−	45 4 y: 41%	NR 5 y: 71%	100	100	− [27]
		MCL	II	56	Consolidation	+(C)	−	+	−	−	94.8	82	55	− [15]
		MCL	II	46	Consolidation (1 st line or R/R)	+(C)	−	+/-	−	1 st line: 39.6 R/R: 26.4	1 st line: 78 R/R: 78	−	91 R/R: 75	− [21]
		MCL	II	56	Consolidation	+(C)	−	+	−	34.2	NR 5 y: 73%	82	55	− [17]
		MCL	P	90	Consolidation (1 st line: 50%, R/R: 50%)	+(C)	−	+	−	25.3	48.6	89 51	67 R/R: 38	− [51]
		MCL	II	162	Late intensifi- cation	+(C)	Auto	+	−	NR 4y: 71%	NR 4y: 78%	−	91	NCT00514475, [38]
		MCL Low-grade B-I NHL		12	R/R	+(C)	−	+	−	6.4	NR	50	42	− [52]
		DLBCL	Retro	63	Conditioning	+(C + R)	Auto	−	−	NR 2 y: 68%	NR 2 y: 90%	−	−	− [39]
		DLBCL	II	30	Conditioning (R/R)	+(C)	Auto	+	−	NR 3 y: 63%	NR 3 y: 61%	70	60	EudraCT 2007- 003198-22, [28]
		DLBCL	II	11	Consolidation	+(C)	Auto	+	−	− 2 y: 18%	− 2y: 36%	−	−	− [16]
		DLBCL	II	62	Consolidation (R/R)	+(C)	−	+	−	FFS median: 15.1	23	50	31	− [22]
		Burkitt Lym- phoma	R	27	Consolidation	−	−	+	−	NR 4 y: 95%	NR 4 y: 95%	−	−	− [53]
		B-NHL	II	20	Conditioning (R/R)	+(C)	Allo	+	−	3 y EFS: 20%	3 y: 20%	−	−	NCT00302757, [29]

		B-NHL	II	20	Conditioning (R/R)	+	(C)	Allo	+	–	12	–	71	64	NCT00644371, [30]
		B-NHL	II	122	Conditioning	+	(C)	Auto	+	–	NR	NR	–	36	NCT00695409, [33]
		B-NHL	II	40	Conditioning	+	(C + TBI)	Allo	+	+	–	–	–	7	NCT00119392, [34]
		B-NHL	Retro	18	Conditioning	+	(C)	Allo	+	–	2.5 y: 31% 3 y: 71%	2.5 y: 54% 3 y: 87%	–	–	[35]
		B-NHL	CS	7	Consolidation (post ASCT)	–		Auto	+	–	–	–	–	71	[54]
		B-NHL	I	30	R/R	+	(I)	–	+	+	42.7	NR	93	63	NCT00438880, [55]
		B-NHL	II	5	R/R	+	(C)	–	+	–	–	–	0	0	NCT01686165, [56]
		B-NHL	I	17	R/R	–		–	+	–	12.3	NR	82	35	NCT00033423, [57]
		MM	I	30	Conditioning	+	(C)	Auto	+	+	16.5	63.4	73	23	NCT00477815, [36]
Rituximab	I-131	FL	II	68	1 st line	–		–	+	–	–	NR	99	82	Australian Clinical Trial Registry No. 12607000153415, [44]
		Low-grade (Ind.) and aggressive (agg.) B-NHL	Retro	36	R/R	–		–	+	–	–	–	Ind.: 2.4 Agg.: 13.4	Ind.: 4.3 Agg.: 6.7	– [59]
		B-NHL	I/II	23	Conditioning (R/R)	+	(C)	Auto	+	–	47.5	101.5	87	64	– [31]
		B-NHL	II	31	R/R	–		–	+	+	9.8	48.2	68	–	– [58]
	Lu-177	MCL	I/II	31	R/R	–		–	+	–	–	–	52	21	– [60]
		B-NHL	P	10	R/R	–		–	+	–	–	–	–	–	– [61]
	Y-90	B-NHL	CS	20	R/R	–		–	+	–	–	–	45	10	– [62]
Tositumomab	I-131	FL	III	532	Consolidation (1 st line)	+	(C)	–	–	–	NR 2 y: 80%	NR 2 y: 93%	84	45	NCT00006721, [18]
		FL	III	531	Consolidation (1 st line)	+	(C)	–	–	–	NR 10 y: 49%	NR 10 y: 78%	98	41	NCT00006721, [20]
		FL	III	14	R/R	–		–	+	–	NR	NR	–	43	NCT00268983, [49]
		Low-grade B-NHL	II	93	R/R	–		–	+	–	12	59.8	43	–	– [63]
		DLBCL	III	224	Conditioning (R/R)	+	(C)	Auto	–	–	– 2 y: 47.9%	NR 2 y: 61%	–	–	NCT00329030, [32]
		DLBCL	II	84	Consolidation (1 st line)	+	(C)	–	+	–	NR 2 y: 69%	NR 2 y: 77%	86	61	NCT00107380, [19]
		DLBCL	II	39	Consolidation (1 st line)	+	(C)	–	+	–	All: 66.5 DLBCL: 36.1 MCL: 69.4	All: 96.2 DLBCL: 36.1 MCL: 5 y: 79%	92.3	82	– [23]
		B-NHL	I	36	Conditioning (R/R)	+	(C)	Auto	+	–	NR 3 y: 53% 10y: 10y:	NR 3 y: 54% 10y: 10y:	–	79	NCT00110071, [64]
		B-NHL	II	107	Conditioning (R/R)	+	(C)	Auto	+	–	All: 61% Low-grade: 64% MCL: 43%	All: 62% Low-grade: 71% MCL: 48%	–	82	– [37]
		B-NHL	CS	39	R/R	–		–	+	–	6.6	–	62	46	– [65]
		B-NHL	I	25	R/R	+	(C)	–	–	–	7	–	64	44	NCT00777114, [66]
		HL	I	12	R/R	–		–	–	–	–	–	–	–	– [67]

¹B-NHL: B-cell non-Hodgkin lymphoma; DLBCL: Diffuse large B-cell lymphoma; FL: Follicular lymphoma; HL: Hodgkin lymphoma; MCL: Mantle cell lymphoma; MM: Multiple myeloma; MZL: Marginal zone lymphoma. ²CS: Case series; P: Prospective; Retro: Retrospective. ³n: Number of patients. ⁴R/R: Relapsed/refractory; SCT: Stem-cell transplantation. ⁵(C): Chemotherapy; (I): Immunotherapy; (R): Radiotherapy; (TBI): Total-body irradiation. CR: Complete response; DFS: Disease-free survival; EFS: Event-free survival; FFS: Failure-free survival; NR: Non-reached; ORR: Overall response rate; OS: Overall survival. *Fractionation concerns RIT protocol.